Current Affairs

Sign in
Science and TechnologyGS3
GS3

Precision Oncology and Active Surveillance for Indolent Cancers

Source:The Hindu ↗

Why It Matters

This topic highlights a crucial intersection of biotechnology (precision medicine, targeted therapies) and healthcare policy. It shows how applied scientific advancements can directly reduce the financial burden of diseases (a major GS2 and GS3 theme) and address the health challenges arising from an aging population and the rise of non-communicable diseases.

Summary

The article discusses a significant paradigm shift in cancer treatment, advocating against the routine use of aggressive treatments like chemotherapy, radiation, and radical surgery for all patients. With advancements in genomics, biomarker tracking, and precision medicine, oncologists can now identify slow-growing or indolent cancers that pose no immediate threat to life. For such cases—often seen in early-stage prostate, thyroid, and some breast cancers—doctors are increasingly adopting 'active surveillance' or 'watchful waiting' over immediate intervention. This transition not only spares patients from the debilitating physical side effects of overtreatment but also significantly reduces the 'financial toxicity' (high out-of-pocket expenditure) associated with modern cancer care, thereby improving overall quality of life.

Key Points

  • Oncology is witnessing a paradigm shift from a 'one-size-fits-all' aggressive treatment approach to precision medicine and patient-specific care.
  • Techniques like 'active surveillance' and 'watchful waiting' are replacing immediate radical surgeries and chemotherapy for slow-growing or indolent cancers (e.g., early-stage prostate, certain thyroid, and breast cancers).
  • Advances in genomics, molecular biology, and biomarker identification allow doctors to accurately risk-stratify tumors, separating aggressive cancers from harmless ones.
  • Avoiding overtreatment minimizes severe physical side effects, improves the patient's quality of life, and curtails the 'financial toxicity' associated with expensive cancer therapies.
  • This trend aligns with a broader push against the over-medicalization and marketization of healthcare, emphasizing rational, evidence-based medical interventions.

Prelims Trap

All diagnosed cancers mandate immediate surgical or radio-chemo interventions to prevent metastasis.

Advances in precision oncology show that many indolent (slow-growing) cancers are safely managed with 'active surveillance' to avoid debilitating overtreatment.

Static Concepts Connected

Science and Technology

What is Precision Medicine and how do biomarkers enable it?

  • Definition: Tailoring medical treatment to individual genetic, environmental, and lifestyle profiles rather than a one-size-fits-all approach.
  • Biomarkers: Measurable biological indicators (e.g., circulating tumor DNA, specific proteins) used to risk-stratify diseases and predict treatment responses.
  • Clinical Benefit: Minimizes adverse drug reactions, avoids the overtreatment of harmless tumors, and ensures targeted therapy.
Social Justice (Health)

What drives High Out-of-Pocket Expenditure (OOPE) in India?

  • Current Status: Despite recent declines due to schemes like Ayushman Bharat, OOPE remains a major driver of medical impoverishment in India.
  • Financial Toxicity: High costs of private diagnostics, targeted NCD therapies, and prolonged care cause severe 'financial toxicity' for vulnerable families.
  • Marketization: Over-reliance on private healthcare and over-medicalization frequently lead to unnecessary, expensive clinical interventions.

Cross-Topic Patterns

  • Patent Monopolies & Financial Toxicity

    The financial toxicity of cancer care is heavily influenced by strict IPR regimes, where patent evergreening inflates the cost of targeted biological therapies and restricts generic competition.

  • Precision Tech in PM-JAY

    Integrating biomarker-driven precision oncology into public schemes like Ayushman Bharat could optimize state resource allocation by preventing expensive, unnecessary overtreatment.

Expect a GS3 prelims/mains question linking 'biomarkers' and 'precision medicine' to health economics and reducing out-of-pocket expenditure.

Linked PYQs · 5

Linked PYQs · 5

  • 2019PrelimsGS1

    'RNA interference (RNAi)' technology has gained popularity in the last few years. Why? 1. It is used in developing gene silencing therapies. 2. It can be used in developing therapies for the treatment of cancer. 3. It can be used to develop hormone replacement therapies. 4. It can be used to produce crop plants that are resistant to viral pathogens. Select the correct answer using the code given below.

  • 2015PrelimsGS1

    With reference to the use of nano-technology in health sector, which of the following statements is/are correct? 1. Targeted drug delivery is made possible by nanotechnology. 2. Nanotechnology can largely contribute to gene therapy. Select the correct answer using the code given below.

  • 2021MainsGS3

    What are the research and developmental achievements in applied biotechnology? How will these achievements help to uplift the poorer sections of the society?

  • 2022MainsGS3

    The increase in life expectancy in the country has led to newer health challenges in the community. What are those challenges and what steps need to be taken to meet them?

  • 2024MainsGS2

    In a crucial domain like the public healthcare system the Indian State should play a vital role to contain the adverse impact of marketisation of the system. Suggest some measures through which the State can enhance the reach of public healthcare at the grassroots level.